Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/25618031http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/25618031http://www.w3.org/2000/01/rdf-schema#comment"

Objective

Homozygosity for a 1.7 kb intragenic duplication of the Haptoglobin (Hp) gene (Hp 2-2 genotype), present in 36% of the population, has been associated with a 2-3 fold increased incidence of atherothrombosis in individuals with Diabetes (DM) in 10 longitudinal studies compared to DM individuals not homozygous for this duplication (Hp 1-1/2-1). The increased CVD risk associated with the Hp 2-2 genotype has been shown to be prevented with vitamin E supplementation in man. We sought to determine if there was an interaction between the Hp genotype and vitamin E on atherosclerotic plaque growth and stability in a transgenic model of the Hp polymorphism.

Methods and results

Brachiocephalic artery atherosclerotic plaque volume was serially assessed by high resolution ultrasound in 28 Hp 1-1 and 26 Hp 2-2 mice in a C57Bl/6 ApoE(-/-) background. Hp 2-2 mice had more rapid plaque growth and an increased incidence of plaque hemorrhage and rupture. Vitamin E significantly reduced plaque growth in Hp 2-2 but not in Hp 1-1 mice with a significant pharmacogenomic interaction between the Hp genotype and vitamin E on plaque growth.

Conclusions

These results may help explain why vitamin E supplementation in man can prevent CVD in Hp 2-2 DM but not in non Hp 2-2 DM individuals."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.org/dc/terms/identifier"doi:10.1016/j.atherosclerosis.2015.01.008"xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Kaplan M."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Haas T."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Zohar Y."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Kam A."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Tamir R."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Asleh R."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Levy A.P."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Levy N.S."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Miller-Lotan R."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Suss-Toby E."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Sabo E."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Ziskind A."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Doros G."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Gorbatov R."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Vardi M."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Shalom H."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Berk T.A."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Goldfarb L.J."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/author"Veiner H.L."xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/name"Atherosclerosis"xsd:string
http://purl.uniprot.org/citations/25618031http://purl.uniprot.org/core/pages"232-239"xsd:string
▶